Divarasib
Divarasib is Roche's KRAS G12C pill, the first to beat the two approved KRAS drugs head-to-head (July 2026).
Covalent G12C inhibitor with ~5-20-fold greater potency than sotorasib/adagrasib in preclinical models; phase 1 ORR 53% in NSCLC. Krascendo 1 (vs sotorasib or adagrasib, previously treated NSCLC) met PFS and OS. Krascendo 2 tests divarasib + pembrolizumab ± chemotherapy first line. FDA orphan designation 2026; filing expected.
Compare all products across the US, EU, UK, Japan, China and Australia →
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Landmark trials in OnCo
Latest papers
topQuery for this drug: (TITLE:"Divarasib" OR ABSTRACT:"Divarasib" OR TITLE:"GDC-6036" OR ABSTRACT:"GDC-6036") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Divarasib, not a curated reading list.
Pages like this
not linked directly; found by shared links- ProductOlomorasib
Shares KRAS & RAS inhibitors, KRAS, Colorectal cancer, Non-small-cell lung cancer.
- ProductElironrasib
Shares KRAS & RAS inhibitors, KRAS, Colorectal cancer, Non-small-cell lung cancer.
- PersonFrank McCormick
Shares KRAS & RAS inhibitors, KRAS, Colorectal cancer, Non-small-cell lung cancer.
- ProductMRTX1133
Shares KRAS & RAS inhibitors, KRAS, Colorectal cancer.
- CompanyFrontier Medicines
Shares KRAS & RAS inhibitors, KRAS, Colorectal cancer, Non-small-cell lung cancer.
- PersonKevan M. Shokat
Shares KRAS & RAS inhibitors, KRAS, Colorectal cancer, Non-small-cell lung cancer.
- ProductAdagrasib
Shares Krascendo 1, KRAS & RAS inhibitors, KRAS, Colorectal cancer.
- TermKRAS mutation subtypes (G12C, G12D, G12V)
Shares KRAS & RAS inhibitors, KRAS, Colorectal cancer, Non-small-cell lung cancer.